Two new broker notes out last week on this one -

Collins Stewart gives a target valuation for the combined entity of 26 million or 156p per share

Edison Investments embedded valuation is 31m - Indicating a 100% gain in share price from current levels. They suggest that using the current embedded valuation model, the current value of Angles six non-exited ventures is only 5.5m - suggesting Angle to be SIGNIFICANTLY UNDERVALUED

Have a look

They are on my wish list - it looks like things may become clearer later this year.

Parsortix Evaluation

Upward trend here....nice....

Learn from the experts



You can now book your free tickets for our big event on Saturday 13 September in partnership with the London Stock Exchange. Held at the Business Design Centre in Islington, North London, The Stock Market Show is a full day event designed to help you understand investing. We have secured a large number of financial experts to explain in simple terms how you should go about investing in the stock market, the ways in which to research individual stocks and how to use different investment and trading accounts.



Tickets for the event are free but must be booked in advance you can also book your seminar sessions on our five separate stages.

The day is about to become a hot talking point among investors across the country as we are very pleased to announce This is Money as our media partner, a website read by millions of people and part of the Daily Mail & General Trust (DMGT) media stable.

• Hear from more than 50 speakers across 5 stages including: product experts, CEOs from listed companies and renowned journalists from Shares including Daniel Coatsworth, Mark Dunne, Steven Frazer and Tom Sieber who will all be giving presentations on investing.

• Speak with over 40 exhibitors from a range of AIM companies brokers and platform providers including: Alecto Minerals, Advanced Computer Software Group, Angle, Avation, Azonto Petroleum, Chaarat Gold, Corero Group Services, eg Solutions, EMIS, Fastnet Oil & Gas, Flowgroup, Fox Marble, Getech, Horizon Discovery, InternetQ, NetDimensions, Nostra Terra Oil & Gas, Premier African Minerals, Valirx, Velocys, Wishbone Gold and XL Media.

• Learn about investment topics tailored to suit a range of investors from novice to expert

• Meet with top financial services providers including; Aberdeen Asset Management, AJ Bell Youinvest, Amati Global Investors, Boost, CMC Markets, ETF Securities, Hargreaves Lansdown, IG, Killik & Co, KPMG, London Stock Exchange, Panmure Gordon, Reyker Securities,Société Générale, Stockopedia and ThisisMoney.


Why you should attend:

We have structured the entire programme around one core principal: financial education



Learn about:

• What you need to become a successful investor

• Managing your own pension using stocks and shares

• The simple approach to valuing companies

• The importance of risk when researching stocks

• The most important areas in company documents and financial accounts

• Reading chart patterns

• An introduction to exchange traded funds and bonds

• Plus a host of other topics on industry sectors, trading techniques, market mechanics and tax issues



Hear from:

• Shares journalists

• Financial services professionals

• Chief executives of quoted companies

• Leading market commentators



Your chance to meet:

• Share dealing and pension providers

• Quoted companies

• Shares journalists

• Representatives from the London Stock Exchange

• Fellow investors

For more information and to register go to: http://www.thestockmarketshow.com/

Could rocket if this becomes some sort of universal standard for cancer cell capture worldwide !.......profits could be staggering !....

"Unprecedented Specificity" in Ovarian Cancer

Well...at least this one looks promising....

Well I don't know about that skinny, but I do know I need a stiff drink after selling too soon! :o)

Not sure about viagra....but as my sharepicking has been hopeless lately.....anyway ; this looks to have fantastic potential !....now I've said that : watch it dive...

Could be a longish haul but for a long term punt it has loads of potential. I was waiting for the sp to pull back a bit before buying back in. I must rename myself as stupidboypike!

200p plus could be on the cards here.

I've been watching for ages, but don't hold either!

Interims tomorrow!

I'm in but I think there has been a mix-up and that this company is in fact Afren......mistakes can happen...

Interim Results for the six months ended 31 October 2014

MOVING CLOSER TO A CLINICAL APPLICATION


ANGLE plc (AIM: AGL and OTCQX: ANPCY), the specialist medtech company, today announces unaudited interim results for the six months ended 31 October 2014.

Highlights

· Collaboration agreements signed with a further five leading international cancer research centres bringing the total number of key opinion leaders working with the Parsortix system to eight covering the UK, Europe and the United States collectively covering breast, colorectal, oesophageal, ovarian, prostate and pancreatic cancers

· Four of the key opinion leaders publicly reported during the period bringing a total of five key opinion leaders reporting positively on their evaluation of the Parsortix system. The remaining three are in progress

· Continued progress towards FDA authorisation

· Second US patent granted relating to improvements in technology and specific use for foetal and cancer applications

· Management team strengthened with US specialist medtech commercialisation experience

· Loss for the half year of £1.6 million (H1 2014: loss £0.5 million) reflecting planned investment in Parsortix of £1.6 million (H1 2014: £1.1 million)

· Cash balance at 31 October 2014 of £2.3 million (30 April 2014: £3.9 million)

Progress post the half year end

· Commercial collaboration established with the diagnostics division of a large pharmaceutical company to investigate the combination of ANGLE's Parsortix circulating tumour cell (CTC) harvesting platform as a front end to the Collaborator's single cell analysis system

· Commercial collaboration established with EKF Diagnostics Holdings plc to investigate the combination of ANGLE's Parsortix circulating tumour cell (CTC) harvesting platform with EKF's PointMan™ DNA enrichment technology as a liquid biopsy to provide a combined solution

· Patient study provides basis for clinical application in ovarian cancer with the Medical University of Vienna reporting the Parsortix system delivers "unprecedented sensitivity and specificity". Following these excellent results in ovarian cancer, ANGLE has commenced a process, in collaboration with the Medical University of Vienna to develop a clinical application for ovarian cancer.

This is looking quite good......Been stocking up with this one.....I've been wrong many a time but....I can imagine a 400p tag on this .....it's just that the sales potential is simply enormous !.....cancer is terrible and this company can trap the bad cells....incredible ...just like a filter....this reminds me of Gulf keystone before the Shaikan oil discovery....in what could be achieved...just wait until a big pharmaceutical company comes along with a mouthwatering offer of some kind....woooossshhh....

Recovering well.....well financed with tremendous potential....one to watch....

Who Should Attend?Date:

Tuesday 31st March 2015

Venue:

Lancashire County Cricket Club, Manchester, Emirates Old Trafford, Talbot Road, Manchester, M16 0PX

Event Timings:Sponsored by:

Sp starting to perform now that the fund raising at 65p is almost out of the way...4 times oversubscribed...

Great update...if they could turn this into commercial orders the sp would fly.....